BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (http://bmjopen.bmj.com/site/about/resources/checklist.pdf) and are provided with free text boxes to elaborate on their assessment. These free text comments are reproduced below.
I assume the GP is the main day to day prescriber, yet the randomisation is based on a hospital doctor. There is potential for various different prescribers having influence, yet not all receiving the advice fro the assessment process. There is potential for cross-group contamination of the intervention through the GPs who may have some patients in the intervention group and others in the control group. Will there be any check of the reproducibility of the assessment made by the adjudicators? e.g blinded double assessment of cases? The protocol publication is late in the day as according to the dates provided, the study is more than half way completed. A relevant related protocol of ours is attached.
The reviewer provided a marked copy with additional comments. Please contact the publisher for full details.
REVIEWER
Sarah Voss University of the West of England, Bristol, UK REVIEW RETURNED 15-Oct-2018 GENERAL COMMENTS This is a well written protocol which clearly describes the rational and design of the study and I recommend it for publication without revisions.

Daniela Melo Federal University of São Paulo -Brazil
REVIEW RETURNED
13-Dec-2018
GENERAL COMMENTS
The study is very interesting and the protocol is very clear and well written. The limitations were evaluated and well reported. Just one comment: the intervention will occur only during the hospital stay and general practitioner will receive information -only described in table 2. Maybe it would be interesting to make that clearer.
The impression I have is that intervention is always performed in the hospital, even by the ease of having "access" to the patient. But the real problem of inappropriate use of medicines, especially for chronic diseases, occurs in the area of primary health care. This aspect could be considered in the discussion. Please leave your comments for the authors below 1) A change in DRA may be offset by a change in overall admissions. Consider primary end point being total admissions.
We have already registered our trial including the pre-specified primary endpoint (first drug-related hospital admission; see page 7, line 27) and all secondary outcomes in the Clinicaltrials.gov database, as requested by the International Committee of Medical Journal Editors. As we have already started patient recruitment, a change in the pre-defined primary endpoint would not be recommended. Overall admissions is a secondary outcome (number of any hospitalisations, as indicated on page 8, line 9).
Moreover, the recent core outcome set for clinical trials of medication review in multimorbid older patients with polypharmacy lists "drug-related admissions" as one of the outcomes to be reported in any clinical trial (ref: Beuscart et al., International core outcome set for clinical trials of medication review in multi-morbid older patients with polypharmacy. BMC Med 2018). Overall admission is not included in this core outcome set. Its measurement as a secondary outcome measure therefore seems appropriate.
We chose DRA as the primary outcome because this trial is supposed to examine the effect of a systematic drug review in multimorbid patients with polypharmacy. Multimorbid elderly are prone to hospital re-admissions not only for drug-related reasons, but also because of their multimorbidity. Therefore, we think this endpoint is particularly suited to show whether a drug review has the potential to reduce hospital admissions in this population.
2) Guideline based decision support for optimising medication use is likely limited by the fact that the guidelines are generally not based on data from multi-morbid populations. However if it works to reduce admissions, all is good.
As indicated in the paragraph "Intervention" on page 6, the decision support tool to optimise medication is based on the established STOPP/START criteria. These criteria have been developed by multiple experts in Geriatric Medicine (who mainly take care of multimorbid patients) and experts in pharmacotherapy of older individuals from various European countries. The criteria were selected based on current evidence from (systematic) reviews and randomised controlled trials, and then presented to the expert panel using a Delphi validation method (see our reference #20). Therefore, the selection of the criteria was not solely guideline-based, but has been influenced by the experience of the expert panel in the treatment of older multimorbid patients. However, we agree that current guidelines are generally not based on data from multimorbid populations, which was also a reason to conduct this trial among multimorbid elderly, as now mentioned in the Discussion on page 11, lines 6-7:
"It will also be one of the largest trials in the growing population of multimorbid older adults that are currently understudied, as they are often excluded from trials 1 ; as a result, clinical guidelines are based on evidence that might not relate to patients with multimorbidity, underlining the need of this trial among elderly patients with multimorbidity."
We have now also provided more information on the STOPP/START criteria in the Introduction on page 3, line 28-32:
"The STOPP/START (Screening Tool of older People's Prescriptions/ Screening Tool to Alert to right treatment) -criteria 20 have been developed by geriatric medicine and pharmacotherapy experts based on review of up-to-date evidence and consensus validation to screen for inappropriate prescribing; they have also been shown to significantly improve medication appropriateness 21 " 3) In multi-morbidity there may be a conscious and rational trade off of risk for quality of life. e.g risk of drug interactions or side effects vs reduction in pain. So some of the secondary end points may be in conflict with each other and maybe in conflict with the primary end point.
We agree with your comment, therefore we will not only assess drug-related hospital admissions as the primary endpoint, but we will also assess quality of life (using the EQ-5D questionnaire including the level of pain/discomfort) and drug-drug interactions as secondary endpoints (as stated on page 8, lines 9-11) to assess whether a structured medication review compared to standard care results in a difference in quality of life or drug-drug interactions. The trial outcomes cover a wide range of different domains and should therefore be able to provide a comprehensive picture of the effects of the intervention. 4) I did not see how patient preference was included.
Shared-decision making with the patient to accommodate patient preference for each medication change was included in our pharmacotherapy optimisation intervention as one of the nine steps of STRIP (Systematic Tool to Reduce Inappropriate Prescribing), as described on page 7, line 9. We have now explicitly indicated this in the sentence on page 7, line 9: "6. Shared decision-making with the patient to take into account patient preferences, again with possible adaptation of recommendations." Please see also the paragraph "Patient and Public Involvement" (page 10, lines 20-34), where the patient and public involvement is now clearly stated, as outlined in our answer to the "formatting amendment" #2 requested by BMJ Open for this revision on page 8 from this letter.
5) It is not clear that each patient will have only one prescribing clinician. With multi-morbidity it may be likely that there are a number of specialty prescribers involved. e.g their GP and their specialist(s). Not clear how many of the prescribers will receive the report and the extent of cross group contamination this will create. A patient / study flow diagram would help.
The trial is conducted in four large hospitals in Europe, where specialists can make suggestions about medical treatments, but one single prescribing physician on the ward has the final responsibility for the patient's treatment and pharmacotherapy and decides whether the specialists' recommendations should be implemented. We have now clarified this on page 4, lines 27-30: "Clusters are defined by the prescribing physician, i.e. the single physician who has the final responsibility for the pharmacotherapy and treatment of patients in the department/ward and also decides on the implementation of potential treatment suggestions made by involved specialists."
The patients' prescribing physician on the ward receives the report with the medication optimisation recommendations and has the final responsibility for the drug therapy. In addition, the patients' GP who will be responsible for the care after hospital discharge also receives a report with the specific recommendations. These steps are outlined in the description of the nine steps of STRIP on page 7, lines 5-14. We hope we have now clarified the patient/study flow with this additional information.
In order to avoid contamination due to a learning effect of the prescribing hospital physician, we use a cluster-randomised trial design, with clusters being defined by the prescribing physician (see page 4, line 27).
If the prescribing physician is absent, clusters will be temporarily closed to avoid bias from cluster contamination or change of prescribing physician, as described on page 11, line 35-36. 6) There is potential for bias in which patients consent to be included, this may limit generalisability. e.g bias to recruiting patients who are better engaged/ more likely adherent to advice/ medications etc. Some comparison of those consenting vs rejecting would help but may be outside of ethics acceptability.
We agree with your concern. Informed consent is mandatory for a study like the OPERAM trial, and the requirement to obtain informed consent might lead to a selection of more engaged patients into the study, potentially limiting the generalisability of the study results; this is an issue in all trials requiring informed consent prior to patient enrolment. To assess potential differences between consenting and non-consenting patients, we will compare selected characteristics such as age or gender between these two groups, as allowed by the ethical boards. We have now added this information to page 12, lines 5-7: "To assess the potential for selection of a specific subpopulation into the trial and better understand generalisability of the study results, we will compare differences in selected characteristics such as age and gender of consenting and non-consenting patients." 7) I assume the GP is the main day to day prescriber, yet the randomisation is based on a hospital doctor. There is potential for various different prescribers having influence, yet not all receiving the advice from the assessment process. There is potential for cross-group contamination of the intervention through the GPs who may have some patients in the intervention group and others in the control group. Please see our answer to your comment #5. The study population consists of hospitalised patients, and recommendations on medication optimisation are provided to the prescribing physician responsible for the patient at the hospital. As the patient's GP also receives a report with the specific recommendations, we agree that there is a potential for contamination through the GP. However, the number of referring GPs is very large, so the number of GPs who have some patients in both the intervention and control groups is likely to be small. We also used partial blinding of GPs who receive only standardised high-level information about the study goals and a document indicating that one of their patients has been included, as described on page 6, line 8-11. We have added this to the limitations on page 11, lines 36-37 and page 12, lines 1-3: "There is a potential for contamination at the level of a patient's GP; however, we use partial blinding of GPs who receive only standardised high-level information about the study goals. Also, the number of GPs with patients in both the intervention and control group is expected to be small, given that the number of GPs referring patients to the enrolling leading university centres is very large." 8) Will there be any check of the reproducibility of the assessment made by the adjudicators? e.g blinded double assessment of cases?
Given budget constraints in a non-industry sponsored trial, adjudication is done in a de-centralised fashion by independent and blinded adjudication teams within study sites who are responsible for adjudicating cases attheir own site. To ensure that criteria are applied in a uniform and correct way, all adjudicators received central training. In addition, all teams adjudicated a common set of cases before trial start and during conduct; these common cases were adjudicated by all teams and results were compared and differences discussed to improve reproducibility. The results of this evaluation have been published in Beuscart, J. B., et al. (2017) . "Development of a core outcome set for medication review in older patients with multimorbidity and polypharmacy: a study protocol." Clin Interv Aging 12: 1379-1389 (our new reference #40).
In addition, to assess the inter-rater reliability of our standardised adjudication guideline to identify drug-related admissions in older people, 30 cases from one study site will be evaluated by adjudicators from all study sites at different time points during the trial. These results will be published as part of a substudy. We have now added this information to the manuscript on page 8, lines 2-4:
"To assess the inter-rater reliability of our standardised adjudication guideline to identify DRA, a certain amount of common cases will be evaluated by adjudicators from all study sites."
9) The protocol publication is late in the day as according to the dates provided, the study is more than half way completed. A relevant related protocol of ours is attached.
Thank you for the interesting protocol. We followed the policy outlined by BMJ Open that protocol manuscripts should report planned or ongoing studies before completion of data collection.
Reviewer: 2 Reviewer Name: Sarah Voss Institution and Country: University of the West of England, Bristol, UK Please state any competing interests or state 'None declared': None declared Please leave your comments for the authors below 1) This is a well written protocol which clearly describes the rational and design of the study and I recommend it for publication without revisions.
Thank you.
Reviewer: 3 Reviewer Name: Daniela Melo Institution and Country: Federal University of São Paulo -Brazil Please state any competing interests or state 'None declared': None declared Please leave your comments for the authors below 1) The study is very interesting and the protocol is very clear and well written. The limitations were evaluated and well reported. Just one comment: the intervention will occur only during the hospital stay and general practitioner will receive information -only described in table 2. Maybe it would be interesting to make that clearer.
We now specifically added the information that the intervention is conducted during the hospital stay of the participant on page 6, line 22: "An unblinded, independent trial team composed of a research physician and pharmacist conducts the intervention during the hospital stay of the study participant."
In addition, we clarified that the recommendations are provided to the prescribing physician in the hospital on page 7, line 5: "Generation of a report with specific recommendations for the prescribing hospital physician."
On page 7, line 13, we have already mentioned that a report with the specific recommendations is provided for the patient's GP.
2) The impression I have is that intervention is always performed in the hospital, even by the ease of having "access" to the patient. But the real problem of inappropriate use of medicines, especially for chronic diseases, occurs in the area of primary health care. This aspect could be considered in the discussion.
Thank you for your important comment; we agree that the identification of inappropriate medication is a problem both in the hospital as well as in the primary care setting. A previous study in communitydwelling elderly patients requiring hospitalisation in Ireland found a prevalence of inappropriate prescribing of 32% (ref: . These results show that inappropriate prescribing occurs equally or perhaps even more so in the inpatient setting, underlining the importance of optimising medications during hospitalisation. A corresponding randomised controlled trial from our research team to specifically investigate medication optimisation using the STRIP intervention in the primary care setting is ongoing (Clinicaltrials.gov NCT 03724539).
3) The authors could consider:
Oscanoa TJ, Lizaraso F, Carvajal A. Hospital admissions due to adverse drug reactions in the elderly. The meta-analysis. Eur J Clin Pharmacol. 2017 Jun; 73 (6): 759-770. Epub 2017 Mar 1.
